Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boveran Diagnostics, a developer of cancer detection technologies, has executed a letter of intent to acquire majority interest in Sophora Diagnostic Lab, a New York-based cancer pathology lab.
Subscribe to our email newsletter
Pursuant to the letter of intent (LOI), Mikhail Kantius will join Boveran Diagnostics as the company’s chief pathologist and director of lab operations and business development for pathology lab services.
Sophora is said to be Boveran’s first planned acquisition and headquarters for its new cancer detection system designs and technologies. Additional acquisitions are planned and will be announced as part of the Boveran’s lab network revenue and growth plan.
Boveran said that it will soon publish guidance on its planned acquisitions, complete business plan information, revenue models, and details on its new development initiative for its next generation fully-automated computer imaging cancer detection platform.